Phase II study of PX-866 in recurrent glioblastoma (Q34458889)

2 August 2017

title

Phase II study of PX-866 in recurrent glioblastoma (English)

1 reference

2 August 2017

13

Suzanne Kamel-Reid

0 references

Ming-Sound Tsao

object named as

Ming Sound Tsao

12

0 references

author name string

Marshall W Pitz

1

1 reference

2 August 2017

Elizabeth A Eisenhauer

2

1 reference

2 August 2017

Mary V MacNeil

3

1 reference

2 August 2017

Brian Thiessen

4

1 reference

2 August 2017

Jacob C Easaw

5

1 reference

2 August 2017

David R Macdonald

6

1 reference

2 August 2017

David D Eisenstat

7

1 reference

2 August 2017

Ankineedu S Kakumanu

8

1 reference

2 August 2017

Muhammad Salim

9

1 reference

2 August 2017

Haji Chalchal

10

1 reference

2 August 2017

Jeremy Squire

11

1 reference

2 August 2017

Shantanu Banerji

14

1 reference

2 August 2017

Dongsheng Tu

15

1 reference

2 August 2017

Jean Powers

16

1 reference

2 August 2017

Diana F Hausman

17

1 reference

2 August 2017

Warren P Mason

18

1 reference

2 August 2017

publication date

20 January 2015

1 reference

2 August 2017

1 reference

2 August 2017

volume

17

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

1270-1274

1 reference

The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Glioblastoma: from molecular pathology to targeted treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

The PI3K pathway as drug target in human cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Targeting the phosphoinositide 3-kinase pathway in cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

IDH1 and IDH2 mutations in gliomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

PI3K inhibitors for cancer treatment: where do we stand?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

PTEN and the PI3-kinase pathway in cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Canadian recommendations for the treatment of glioblastoma multiforme.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Temporal trends in incidence of primary brain tumors in the United States, 1985-1999

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

High frequency of mutations of the PIK3CA gene in human cancers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

6 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU365

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU365

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU365

Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU365

Multinomial phase II cancer trials incorporating response and early progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU365

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

Response criteria for phase II studies of supratentorial malignant glioma

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588751

A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25605819

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOU365

1 reference

2 August 2017

1 reference

2 August 2017

1 reference